Sustaining Innovation Analyst Day

IR thematic call on sarilumab

  1. Home
  2. Investors
  3. Financial results and events
  4. Investor presentations
  5. IR thematic call on sarilumab

Sanofi and Regeneron hosted a conference call for the financial community on sarilumab during the American College of Rheumatology Annual (ACR) Meeting in San Francisco.

Sarilumab is a fully-human monoclonal antibody directed against the IL-6 receptor (IL-6R). This investigational compound is currently in clinical development for Rheumatoid Arthritis. Sarilumab achieved primary efficacy endpoints across all completed pivotal Phase 3 studies, including for TARGET and ASCERTAIN. Data from these two studies were presented as oral presentations at ACR on November 8th.

Related press releases